Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $38.94 USD
Change Today -0.43 / -1.09%
Volume 230.5K
As of 8:04 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

wuxi pharmatech cayman-adr (WX) Snapshot

Open
$39.44
Previous Close
$39.37
Day High
$39.44
Day Low
$38.33
52 Week High
02/13/15 - $42.31
52 Week Low
05/15/14 - $29.84
Market Cap
2.8B
Average Volume 10 Days
483.1K
EPS TTM
$1.37
Shares Outstanding
71.5M
EX-Date
--
P/E TM
28.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for WUXI PHARMATECH CAYMAN-ADR (WX)

wuxi pharmatech cayman-adr (WX) Related Businessweek News

No Related Businessweek News Found

wuxi pharmatech cayman-adr (WX) Details

Wuxi PharmaTech (Cayman) Inc. operates as a pharmaceutical, biotechnology, and medical device research and development services company in China and the United States. It operates through two segments, Laboratory Services and Manufacturing Services. The Laboratory Services segment offers services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical, genomics, bioinformatics, research reagent production, and clinical services; services for discovery and development of biologics; and laboratory services, including testing services for biologics, medical devices, and combination products, as well as production of cell therapies. The Manufacturing Services segment provides manufacturing services, including development of manufacturing processes; and the production of advanced intermediates and active pharmaceutical ingredients for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products, and in commercial products, as well as the production of biologic products. The company sells its products to pharmaceutical, biotechnology, and medical device companies, as well as academic institutions and non-profit organizations. Wuxi PharmaTech (Cayman) Inc. was founded in 2000 and is headquartered in Shanghai, China.

8,837 Employees
Last Reported Date: 04/15/15
Founded in 2000

wuxi pharmatech cayman-adr (WX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

wuxi pharmatech cayman-adr (WX) Key Developments

Wuxi Pharmatech (Cayman) Inc. to Build New Cell Therapy Manufacturing Facility for CAR T Cells and Other Cancer Immunotherapies

WuXi PharmaTech (Cayman) Inc. announced that it will soon begin construction of a new, 145,000-square-foot cGMP facility in Philadelphia for the manufacture of cell therapy products. This facility is designed for cell therapy products that contain viral vectors such as chimeric antigen receptor T cell (CAR T cell) therapies. CAR T cells are T cells harvested from a patient's body, engineered to target specific cancers, and then reintroduced into the body. The new facility will become WuXi's third cell therapy manufacturing facility when it becomes operational by mid-2016. It will provide single-source contract development and cGMP manufacturing capabilities to support the rapidly growing cellular therapeutic industry's unique requirements. Specifically, the new facility will provide manufacturing capability and capacity to meet the rapidly expanding demand for clinical studies and commercial supply. The new facility will expand upon WuXi's existing 16,000-square-foot cGMP cell therapy manufacturing facility, as well as a 45,000-square-foot facility for the manufacturing of allogeneic and autologous cell-based therapeutics that is expected to be completed by mid-2015. By 2016, WuXi's available manufacturing capacity in the U.S. of 206,000 square feet would help meet the anticipated market needs of clinical and commercial production for cell-therapy companies. These facilities will complement the company's current fully integrated facility for biological safety and lot release testing in Philadelphia.

Wuxi Pharmatech (Cayman) Inc. Announces Unaudited Consolidated Earnings Results for the Fourth and Full Year Ended December 31, 2014; Provides Earnings Guidance for the First Quarter and Full Year 2015

WuXi PharmaTech (Cayman) Inc. announced unaudited consolidated earnings results for the fourth and full year ended December 31, 2014. For the quarter, total net revenues were $190,650,000 against $157,172,000 for the same period a year ago. Operating income was $24,561,000 against $29,365,000 for the same period a year ago. Income before income taxes was $39,653,000 against $40,739,000 for the same period a year ago. Net income was $33,000,000 or $0.46 diluted per share against $32,858,000 or $0.45 diluted per share for the same period a year ago. Non-GAAP operating income was $31,386,000 against $35,589,000 for the same period a year ago. Non-GAAP net income was $39,721,000 against $39,065,000 for the same period a year ago. Diluted earnings per ADS (Non-GAAP) were $0.55 against $0.53 for the same period a year ago. GAAP operating income decreased 16.4% year over year due to merger and acquisition related transaction costs, increased selling and marketing expenses, higher general and administrative expenses including compensation cost of management due to business expansion, and increased research and development expenses in biologics, discovery biology, genomics, and other areas, partially offset by the 18.0% increase in gross profit. Non-GAAP net income increased 1.7% year over year due to $6.9 million of gains on the sale of investments by the corporate venture fund. For the year, total revenues were $674,279,000 against $578,082,000 for the same period a year ago. Operating income was $103,728,000 against $105,244,000 for the same period a year ago. Income before income taxes was $136,611,000 against $138,031,000 for the same period a year ago. Net income was $112,158,000 or $1.56 diluted per share against $114,567,000 or $1.57 diluted per share for the same period a year ago. Non-GAAP operating income was $127,104,000 against $123,379,000 for the same period a year ago. Non-GAAP net income was $135,380,000 against $132,619,000 for the same period a year ago. Diluted earnings per ADS (Non-GAAP) were $1.88 against $1.82 for the same period a year ago. Non-GAAP net income increased 2.1% year over year due to the 3.0% year-over-year increase in non-GAAP operating income. Non-GAAP diluted earnings per ADS increased 3.0% year over year due to the 2.1% increase in non-GAAP net income and a slightly lower number of outstanding ADSs as a result of share purchases earlier in the year. GAAP diluted earnings per ADS decreased 1.2% to $1.56 due to the 2.1% decrease in net income, partially offset by a slightly lower number of outstanding ADSs as a result of share purchases earlier in the year. GAAP operating income decreased 1.4% year over year due to merger and acquisition related transaction costs, increased selling and marketing expenses, higher general and administrative expenses including compensation cost of management due to business expansion, and increased research and development expenses in biologics, discovery biology, genomics, and other areas, partially offset by the 19.0% increase in gross profit. GAAP net income decreased 2.1% year over year due to the 1.4% year-over-year decrease in operating income. Capital expenditures were $108 million mainly for building large small-molecule manufacturing facilities, a cell therapy manufacturing facility, purchase of Illumina HiSeq X Ten sequencing instrument, IT infrastructure and laboratory expansions. The company provided earnings guidance for the year 2015. For the year, the company expected total net revenues of $790 million to $800 million, GAAP diluted earnings per ADS of $1.31 to $1.36, non-GAAP diluted earnings per ADS of $1.73 to $1.78 and capital expenditures of $180 to $200 million. The company expects negative cash flow in 2015 due to high-level investment. The company provided earnings guidance for the first quarter of 2015. For the quarter, the company expected total net revenues of $173 million to $175 million, GAAP diluted earnings per ADS of $0.20 to $0.22 and non-GAAP diluted earnings per ADS of $0.30 to $0.32.

WuXi PharmaTech (Cayman) Inc. Enters into Syndicated Loan Agreement

WuXi PharmaTech (Cayman) Inc. announced that it has entered into a syndicated loan facility to borrow up to $165 million from a consortium of banks in Asia led by Citibank. The borrowing will incur interest at a rate of LIBOR plus 2.89%, including all expenses, and will be repaid in four installments over 18-36 months.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WX:US $38.94 USD -0.43

WX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Charles River Laboratories International Inc $78.54 USD +0.28
Ergomed PLC 166.50 GBp 0.00
Hangzhou Tigermed Consulting Co Ltd CNY74.60 CNY +0.95
PAREXEL International Corp $69.55 USD +0.90
View Industry Companies
 

Industry Analysis

WX

Industry Average

Valuation WX Industry Range
Price/Earnings 25.3x
Price/Sales 4.1x
Price/Book 3.6x
Price/Cash Flow 24.6x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WUXI PHARMATECH CAYMAN-ADR, please visit www.wuxiapptec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.